相关实验视频

Updated: Feb 20, 2026

Surface Enhanced Raman Spectroscopy Detection of Biomolecules Using EBL Fabricated Nanostructured Substrates

Surface Enhanced Raman Spectroscopy Detection of Biomolecules Using EBL Fabricated Nanostructured Substrates

Published on: March 20, 2015

基于Au-COF基质的抗兴奋剂β₂-agonists的SERS指纹检测

Siqing Liu¹, Liping Chen², Xingju Li²

¹School of Food and Bioengineering, Xihua University, Chengdu, 610039, China; School of Science, Xihua University, Chengdu, 610039, China.

Analytica chimica acta

|February 18, 2026

概括

这项研究引入了一种使用金纳米粒子和共价有机框架 (Au-COF) 的新方法,用于高度敏感地检测β2-激动剂. 这种先进的技术为医疗安全和反兴奋剂工作提供了有前途的应用.

科学领域:

分析化学分析化学
材料科学材料科学材料科学
生物化学生物化学

背景情况:

β2-激动剂是用于治疗喘的甲醇胺,但由于性能提高和依赖风险,WADA禁止使用.
目前的β2-激动剂检测方法可能缺乏对微量剂的必要灵敏度.

研究的目的:

开发一种新的,高度灵敏的β2-激动剂检测平台.
建立一种直接的拉曼检测技术,用于分析β2-激动剂化合物.

主要方法:

通过氧化还原方法合成金纳米粒子 (AuNPs).
整合AuNPs与共价有机框架 (COF),以创建一个Au-COF复合材料.
利用表面增强拉曼光谱法 (SERS) 直接检测和分析β2-激动剂.

主要成果:

成功获得了三种β2-激动剂的指纹光谱:维兰醇,醇和竹醇.
新型Au-COF复合材料平台显示了高吸附率,并显著增强了SERS信号.
达到的低检测极限:7.54 × 10−6 g·mL−1 (芬醇),9.25 × 10−6 g·mL−1 (班布醇) 和9.76 × 10−6 g·mL−1 (维兰特醇).

结论:

开发了一种使用Au-COF复合材料的新型分析方法,用于高度敏感的SERS检测微量β2-激动剂.
开创了这种策略的应用,用于对β2-激动剂的定性和定量分析.
该方法在临床药物监测和体育反兴奋剂检测方面具有重大实际价值.

关键词:

在竹子上,他用了子.协价有机框架协价有机框架芬诺醇的使用方法表面增强的拉曼光谱学维兰特罗尔 (Vilanterol) 是一种这种药物是 β(2) - - 激动剂.

更多相关视频

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Author Spotlight: Advancing SERS Technology: Au@Carbon Dot Nanoprobes for Label-Free Analysis and Imaging

Author Spotlight: Advancing SERS Technology: Au@Carbon Dot Nanoprobes for Label-Free Analysis and Imaging

Published on: June 9, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...